SCHEMBL1066767

SCHEMBL1066767

CC(C)(C)OC(=O)NCCOCCOC(=O)NCCOCCOC(=O)NCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
IDO1 P14902 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA12 O43570 3/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA9 Q16790 3/20 0.43
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
SUCNR1 Q9BXA5 2/20 0.41
ACHE P22303 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BCHE P06276 1/20 0.38
CNR2 P34972 1/20 0.38
ADRB2 P07550 1/20 0.37
HTR1A P08908 1/20 0.37
EPHX1 P07099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1060871 1.00 MEN1 (0.44) MEN1GAAKMT2AIDO1TDP1
SCHEMBL14191660 1.00 MEN1 (0.44) MEN1GAAKMT2AIDO1TDP1
SCHEMBL1064591 1.00 MEN1 (0.44) MEN1GAAKMT2AIDO1TDP1
SCHEMBL14264537 0.88 MEN1 (0.44) MEN1GAAKMT2AIDO1TDP1
SCHEMBL18360370 0.86 TDP1 (0.46) MEN1GAAKMT2AIDO1TDP1
SCHEMBL1064998 0.86 ACHE (0.41) MEN1GAAKMT2AIDO1TDP1
SCHEMBL1061879 0.86 ACHE (0.41) MEN1GAAKMT2AIDO1TDP1
SCHEMBL3361834 0.86 ACHE (0.41) MEN1GAAKMT2AIDO1TDP1
SCHEMBL14281321 0.85 MAOA (0.50) MEN1GAAKMT2AIDO1TDP1
SCHEMBL21069250 0.85 TDP1 (0.53) MEN1GAAKMT2AIDO1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450469-B2 Synthesis of peptide nucleic acids conjugated with amino acids and their application PANAGENE INC. (KR) 2013-05-28 US disclosed
US-20110014715-A1 Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application PANAGENE INC. (KR) 2011-01-20 US disclosed
WO-2009093821-A9 SYNTHESIS OF PEPTIDE NUCLEIC ACIDS CONJUGATED WITH AMINO ACIDS AND THEIR APPLICATION 주식회사 파나진 (KR) 2010-05-27 WO disclosed
WO-2009093821-A2 SYNTHESIS OF PEPTIDE NUCLEIC ACIDS CONJUGATED WITH AMINO ACIDS AND THEIR APPLICATION PANAGENE INC. (KR) 2009-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110014715-A1 Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application CPSF6, RNGTT, DNPEP MEN1 4198/4885GAA 515/4885KMT2A 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.